Pancreatic Cancer Research

ResearcherKarolinska University HospitalActive in the last 2 years

Carlos Fernández Moro

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6863-5959; OpenAlex author ID A5025483481. Sources: OpenAlex.

Their work

Papers
25 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
72
Papers, trials and grants by year

2017: 2 papers · 2018: none · 2019: 5 papers · 2020: 1 paper · 2021: 3 papers · 2022: 2 papers · 2023: 1 paper · 2024: 3 papers · 2025: 3 papers · 2026: 5 papers

Papers 25

  1. Circulating tumour DNA as a prognostic tool for surgically treated pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.humpath.2025.106024↗
  2. Transcriptomic profiling reveals complement activation in chronic pancreatitis adjacent to pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.imbio.2026.153239↗
  3. Multiple R1 margins are associated with shorter overall survival: national register-based study on pancreatic cancer. First author DOI 10.1093/bjsopen/zrag155↗
  4. Granular cell tumor of the pancreas mimicking pancreatic ductal adenocarcinoma: a case report. Co-author DOI 10.1186/s12876-026-05155-z↗
  5. Selenite modulates phenotype-dependent epithelial-mesenchymal plasticity in pancreatic ductal adenocarcinoma: integrated in vitro analyses and patient-derived … Co-author DOI 10.1186/s13046-026-03778-4↗
  6. Performance of MRI-based surveillance for high-risk individuals for pancreatic cancer. Co-author DOI 10.1016/j.ejrad.2025.112275↗
  7. An anti-CEA affibody showing high-definition staining in human pancreatic cancer tissue sections and selective tumor targeting in vivo. First author DOI 10.1016/j.tranon.2025.102512↗
  8. An injury-associated lobular microniche is associated with the classical tumor cell phenotype in pancreatic cancer. Co-author DOI 10.1038/s41467-025-63864-7↗
  9. Consistency of a clinical decision support system with molecular tumour board recommendations for tumour sequencing-guided treatment of pancreatic cancer. Co-author DOI 10.1016/j.esmogo.2024.100070↗
  10. Genderized Gut and Oral Microbiome Shifts: Uncovering Sex-Specific Dysbiosis in Pancreatic Cancer Co-author DOI 10.1101/2024.10.02.616338↗
  11. Exhausted Tumor-infiltrating CD39+CD103+ CD8+ T Cells Unveil Potential for Increased Survival in Human Pancreatic Cancer. First author DOI 10.1158/2767-9764.crc-23-0405↗
  12. Exploration of Patient-Derived Pancreatic Ductal Adenocarcinoma Ex Vivo Tissue for Treatment Response. Co-author DOI 10.3390/antiox12010167↗
  13. Author Correction: Integrated targeted metabolomic and lipidomic analysis: A novel approach to classifying early cystic precursors to invasive pancreatic cance… Co-author DOI 10.1038/s41598-022-08527-z↗
  14. Drug-induced tumor-specific cytotoxicity in a whole tissue ex vivo model of human pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2022.965182↗
  15. Extracellular vesicles are the primary source of blood-borne tumour-derived mutant KRAS DNA early in pancreatic cancer. Co-author DOI 10.1002/jev2.12142↗
  16. Stabilization of the classical phenotype upon integration of pancreatic cancer cells into the duodenal epithelium. First author DOI 10.1016/j.neo.2021.11.007↗
  17. Isolation of pancreatic microbiota from cystic precursors of pancreatic cancer with intracellular growth and DNA damaging properties. Co-author DOI 10.1080/19490976.2021.1983101↗
  18. Genome-wide transcriptome profiling of ex-vivo precision-cut slices from human pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41598-020-65911-3↗
  19. Immunohistochemical profiling of liver metastases and matched-pair analysis in patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2019.09.005↗
  20. Neoepitope targets of tumour-infiltrating lymphocytes from patients with pancreatic cancer. Co-author DOI 10.1038/s41416-018-0262-z↗
  21. Ex vivo organotypic culture system of precision-cut slices of human pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41598-019-38603-w↗
  22. Integrated targeted metabolomic and lipidomic analysis: A novel approach to classifying early cystic precursors to invasive pancreatic cancer. Co-author DOI 10.1038/s41598-019-46634-6↗
  23. Enrichment of oral microbiota in early cystic precursors to invasive pancreatic cancer. Co-author DOI 10.1136/gutjnl-2018-317458↗
  24. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. Co-author DOI 10.1002/1878-0261.12108↗
  25. Stroma-regulated HMGA2 is an independent prognostic marker in PDAC and AAC. Co-author DOI 10.1038/bjc.2017.140↗

Closest collaborators

The 25 strongest of 72 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mikael Björnstedt · 9 shared papers, 2019–2026 · strength 1.84
  2. Matthias J. Löhr · 10 shared papers, 2017–2025 · strength 1.44
  3. Poya Ghorbani · 5 shared papers, 2024–2026 · strength 1.20
  4. Joakim Dillner · 5 shared papers, 2020–2026 · strength 1.14
  5. Mehran Ghaderi · 5 shared papers, 2020–2026 · strength 1.14
  6. Ernesto Sparrelid · 4 shared papers, 2024–2026 · strength 1.00
  7. Arun Kumar Selvam · 4 shared papers, 2022–2026 · strength 0.90
  8. Raffaella Pozzi Mucelli · 3 shared papers, 2024–2026 · strength 0.88
  9. Tímea Szekerczés · 3 shared papers, 2023–2026 · strength 0.72
  10. Béla Bozóky · 4 shared papers, 2021–2025 · strength 0.67
  11. Margaret Chen · 5 shared papers, 2019–2024 · strength 0.63
  12. Rainer Lothar Heuchel · 5 shared papers, 2017–2024 · strength 0.54
  13. Marco Del Chiaro · 4 shared papers, 2019–2024 · strength 0.51
  14. Marco Gerling · 3 shared papers, 2021–2025 · strength 0.47
  15. Nikolaos Kartalis · 2 shared papers, 2024–2025 · strength 0.45
  16. Marco Del Chiaro · 5 shared papers, 2017–2021 · strength 0.44
  17. Mátyás Béndek · 1 shared paper, 2026 · strength 0.43
  18. Stefan Gilg · 1 shared paper, 2026 · strength 0.43
  19. Caroline Sophie Verbeke · 5 shared papers, 2017–2020 · strength 0.43
  20. Rogier Aäron Gaiser · 4 shared papers, 2019–2022 · strength 0.42
  21. Roberto Valente · 4 shared papers, 2019–2022 · strength 0.42
  22. Carina Strell · 3 shared papers, 2017–2025 · strength 0.37
  23. Patrik Larsson · 1 shared paper, 2026 · strength 0.36
  24. Bobby Tingstedt · 1 shared paper, 2026 · strength 0.36
  25. Melroy Alistair D'souza · 1 shared paper, 2026 · strength 0.36

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.